LANDIS INTERNATIONAL
R & D MANAGEMENT

RECEIVED
OPPT CBIC

2015 APR 16 PM 12: 27

CBIC Control Number
364700

April 14, 2015

VIA FEDERAL EXPRESS

United States Environmental Protection Agency - East
ATTN: TSCA Section 8(e)
Room 6428
1201 Constitution Avenue, NW
Washington, DC 20004-3302

SUBJECT: Notice in Accordance with TSCA Section 8(e): Results of a range finding inhalation toxicity study, rat (5 exposures, dust) with MCI-8007, conducted by BASF SE, Ludwigshafen, Germany.

Dear Sir/Madam:

LANDIS INTERNATIONAL, INC. (hereinafter LANDIS), Consultant and Regulatory Agent herein submits on behalf of MITSUI CHEMICALS AGRO, INC., EPA Company Number 86203, data which we believe to be reportable under TSCA 8(e). The information concerns results of a range finding inhalation toxicity study, rat (5 exposures, dust) with MCI-8007, an experimental pesticide.

The purpose of this study was to determine appropriate doses for an inhalation toxicity study in the rat.

EXP-8007 is *N*-[2-bromo-6-trifluoromethyl-4-(perfluoropropane-2-yl-phenyl]-2-fluoro-3-(*N*-methylbenzamide)benzamide, the structure of which is shown in the following figure:



MCI-8007

Groups of five male and five female Wistar rats were head-nose exposed to dynamic inhalation atmosphere of MCI-8007 for 6 hours a day, on 5 consecutive days. The targeted concentrations were 100 mg/m³, 300 mg/m³ and 1000 mg/m³ MCI-8007 as a dust aerosol. A concurrent control group of five male and five female animals was exposed to fresh air.

3185 Madison Highway □ P.O. Box 5126 □ Valdosta, Georgia 31603-5126 USA □ (229) 247-6472 □ Fax (229) 242-1562 □
landis@landisintl.com

Clinical observations and body weight determinations were performed for all animals. Hematological and clinical chemical examination of parameters according to the OECD TG 412 was performed at the end of the exposure period.

The animals underwent gross necropsy after last exposure including gross pathological evaluation and organ weight assessment. Histological examination of the respiratory tract (nasal cavity (4 levels), larynx (3 levels), trachea (transverse and longitudinal section), tracheobronchial and mediastinal lymph nodes), adrenal glands, liver, ovaries and spleen was performed.

The following substance-related adverse finding was observed:

At 1000 mg/m^3

- Minimal to slight inflammatory cell infiltrates in the bronchio-alveolar transition region in all males and females.
- Slight hypertrophy/hyperplasia of terminal bronchioles in all males and females.

LANDIS understands that reporting of results from this study under TSCA 8(e) is in accordance with EPA's policy.

Please feel free to contact Richard H. Collier at (229) 247-6472 or dcollier@landisintl.com if any questions arise or further information is required.

Best regards,

Richard H. Collier
Regulatory Agent for
MITSUI CHEMICALS AGRO, INC.

3185 Madison Highway □ P.O. Box 5126 □ Valdosta, Georgia 31603-5126 USA □ (229) 247-6472 □ Fax (229) 242-1562 □
landis@landisintl.com

ORIGIN ID:VLDA (229) 247-6472
RICHARD COLLIER
LANDIS INTERNATIONAL
3185 MADISON HWY

VALDOSTA, GA 31601
UNITED STATES US

SHIP DATE: 15APR15
ACTWGT: 1.0 LB
CAD: 4101554/INET3610

BILL SENDER

TO US EPA - EAST
ATTN: TSCA SECTION 8(E)
ROOM 6428
1201 CONSTITUTION AVENUE, NW
WASHINGTON DC 20004

(229) 247-6472 REF:
INV:
PO: DEPT:

537J2/8FC5/EE4B

FedEx Express

J151215022301uv

THU - 16 APR AA

TRK# 7733 7728 9130 STANDARD OVERNIGHT

4
D

XC RDVA

20004
DC-US
IAD

FedEx.

TRK# 7733 7728 9130 0201

THU - 16 APR AA
STANDARD OVERNIGHT